Joel R. Pekow to Prospective Studies
This is a "connection" page, showing publications Joel R. Pekow has written about Prospective Studies.
Connection Strength
0.316
-
Comparison of the Risk of Crohn's Disease Postoperative Recurrence Between Modified Rutgeerts Score i2a and i2b Categories: An Individual Patient Data Meta-analysis. J Crohns Colitis. 2023 Mar 18; 17(2):269-276.
Score: 0.123
-
Real World Clinical Effectiveness and Safety of Ozanimod in the Treatment of Ulcerative Colitis: 1-Year Follow-Up from a Tertiary Center. Dig Dis Sci. 2024 Feb; 69(2):579-587.
Score: 0.032
-
The Development and Initial Findings of A Study of a Prospective Adult Research Cohort with Inflammatory Bowel Disease (SPARC IBD). Inflamm Bowel Dis. 2022 02 01; 28(2):192-199.
Score: 0.028
-
Fecal Microbiota Transplantation Is Highly Effective in Real-World Practice: Initial Results From the FMT National Registry. Gastroenterology. 2021 01; 160(1):183-192.e3.
Score: 0.026
-
Lack of Difference in Treatment Patterns and Clinical Outcomes Between Black and White Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 11 29; 24(12):2634-2640.
Score: 0.023
-
A comparison of the risk of postoperative recurrence between African-American and Caucasian patients with Crohn's disease. Aliment Pharmacol Ther. 2018 11; 48(9):933-940.
Score: 0.022
-
Risk Factors for Clostridium difficile Isolation in Inflammatory Bowel Disease: A Prospective Study. Dig Dis Sci. 2018 04; 63(4):1016-1024.
Score: 0.022
-
The benefit of combination therapy depends on disease phenotype and duration in Crohn's disease. Aliment Pharmacol Ther. 2017 07; 46(2):162-168.
Score: 0.020
-
Zinc Deficiency is Associated with Poor Clinical Outcomes in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017 01; 23(1):152-157.
Score: 0.020